Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-provided claim is fully supported by the supplied FDA label excerpt for Section 2.6 Administration Options, including adult crushing with applesauce, food-following for 15 mg/20 mg, NG/gastric tube suspension in 50 mL water with the distal-to-stomach absorption caution, post-dose feeding requirements for 15 mg/20 mg, and the pediatric feeding follow-up differences (recurrent VTE vs Fontan).
Category Scores
Accurate Statements
XARELTO tablets may be crushed and mixed with applesauce immediately prior to use for adult patients unable to swallow whole tablets.
Supported by Section 2.6 Administration Options (adults unable to swallow whole tablets; crushed tablets mixed with applesauce immediately prior to use).
For 15 mg or 20 mg tablets, the dose should be immediately followed by food.
Supported by Section 2.6 (after administration of a crushed XARELTO 15 mg or 20 mg tablet, dose should be immediately followed by food; administration with food not required for 2.5 mg or 10 mg tablets).
For NG/gastric tube administration, crushed tablets may be suspended in 50 mL water after confirming tube placement.
Supported by Section 2.6 (after confirming gastric placement, may be crushed and suspended in 50 mL of water and administered via NG or gastric feeding tube).
Avoid administration distal to the stomach to prevent reduced absorption.
Supported by Section 2.6 (since rivaroxaban absorption is dependent on site of drug release, avoid administration distal to the stomach which can result in reduced absorption and reduced drug exposure).
After 15 mg or 20 mg via NG/gastric feeding tube, immediately follow with enteral feeding; enteral feeding not required for 2.5 mg or 10 mg.
Supported by Section 2.6 (after administration of a crushed XARELTO 15 mg or 20 mg tablet, dose should be immediately followed by enteral feeding; enteral feeding not required for 2.5 mg or 10 mg tablets).
Crushed tablets and NG tube tubing compatibility are described (including in vitro compatibility).
Supported by Section 2.6 (stability in water and applesauce up to 4 hours; in vitro compatibility study with PVC or silicone NG tubing).
XARELTO oral suspension may be given through NG or gastric feeding tube and the tube should be flushed with water.
Supported by Section 2.6 (administration of XARELTO suspension via NG/gastric tube; after administration, flush the feeding tube with water).
Pediatric: for treatment/reduction in risk of recurrent VTE, feed immediately after dosing to increase absorption; for Fontan thromboprophylaxis, feeding is not required after dosing.
Supported by Section 2.6 (pediatric VTE treatment/reduction in risk: dose should then be immediately followed by enteral feeding to increase absorption; Fontan thromboprophylaxis: dose does not require to be followed by enteral feeding).
Unsupported Statements
2.6 Administration Options: XARELTO tablets may be crushed and mixed with applesauce immediately prior to use for adult patients unable to swallow whole tablets; for 15 mg or 20 mg tablets, the dose should be immediately followed by food; for NG/gastric feeding tube administration, crushed tablets may be suspended in 50 mL water after confirming tube placement, but avoid administration distal to the stomach to prevent reduced absorption; after 15 mg or 20 mg tablet via NG/gastric feeding tube, immediately follow with enteral feeding; crushed tablets and NG tube tubing compatibility are described; XARELTO oral suspension may be given through NG or gastric feeding tube and the tube should be flushed; pediatric VTE/reduction and Fontan thromboprophylaxis feeding requirements are specified.
No unsupported sub-elements identified; all components are stated in the provided Section 2.6 excerpt.
Contradictions
Important Omissions
No omissions identified that are material to the claim’s stated administration mechanics and pediatric feeding requirements (the claim is limited to Section 2.6 content).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Because the claim mirrors the provided label instructions for crushing/administration via applesauce and NG/gastric tube, including strength-specific food/feeding requirements and the distal-to-stomach absorption caution, the risk of label-mismatch from these statements is low.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement